Research Article
BibTex RIS Cite

Year 2021, Volume: 42 Issue: 4, 758 - 765, 29.12.2021

Nazlı İşlen , Mehmet Rıfkı Topçul

https://izlik.org/JA93HL44GS

Abstract

Supporting Institution

İstanbul Üniversitesi Bilimsel Araştırma Projeleri Birimi

Project Number

FYL-2016-21025

Thanks

This work was supported by Scientific Research Projects Coordination Unit of Istanbul University. Project no: FYL-2016-21025. Bu çalışma İstanbul Üniversitesi Bilimsel Araştırma Projeleri Birimi tarafından desteklenmiştir. Proje no: FYL-2016-21025.

References

  • [1] Russo J., Russo I.H., Development of The Human Breast, Maturitas, 49(1) (2004) 2-15.
  • [2] Bahreyni A., Samani S.S., Rahmani F., Behnam‐Rassouli R., Khazaei M., Ryzhikov M. et al., Role of Adenosine Signaling in The Pathogenesis of Breast Cancer, Journal of Cellular Physiology, 233(3) (2018) 1836-1843.
  • [3] Topçul M., Çetin İ., Breast Cancer, Cancer: Disease of the Age, In: (Ed.) Ahmed M El-Sharkawy, Chapter 19, OMICS Group eBooks, Foster City, USA, (2015) 1-21.
  • [4] Board P.C.G.E., Genetics of Breast and Gynecologic Cancers (PDQ®), (2016).
  • [5] Schulz W.A., Breast Cancer, In: Schulz WA (Ed.). Molecular Biology of Human Cancers, Springer, Germany, (2005) 357-382.
  • [6] Weber G.F., Epithelial Tumors, In: Weber GF (Ed.). Molecular Mechanisms of Cancer, Springer, USA, (2007) 441-524.
  • [7] Tryggvadottir L., Olafsdottir E.J., Gudlaugsdottir S., Thorlacius S., Jonasson J.G., Tulinius H. et al., BRCA2 Mutation Carriers, Reproductive Factors and Breast Cancer Risk, Breast Cancer Research, 5(5) (2003) R121.
  • [8] Narod S.A., Modifiers of Risk of Hereditary Breast and Ovarian Cancer, Nat. Rev. Cancer, 2 (2002) 113-123.
  • [9] Vidarsson H., Mikaelsdottir E.K., Rafnar T., Bertwistle D., Ashworth A., Eyfjord J.E. et al., BRCA1 and BRCA2 Bind Stat5a and Suppress Its Transcriptional Activity, FEBS Letters, 532(1-2) (2002) 247-252.
  • [10] Yarden Y., Ullrich A., Growth Factor Receptor Tyrosine Kinases, Annu Rev Biochem., 57 (1988) 443-478.
  • [11] Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R. et al., Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer, Gene, 366(1) (2006) 2-16.
  • [12] Demirelli F.H., Hedefe yönelik kanser tedavisi ve monoklonal antikorlar, Antibiyotik ve Kemoterapi Derneği (ANKEM) Dergisi, 19 (2005) 123-125.
  • [13] Mehrabi M., Mansouri K., Soleymani B., Hoseinkhani Z., Shahlaie M., Khodarahmi R., Development of A Human Epidermal Growth Factor Derivative with EGFR-Blocking and Depleted Biological Activities: A Comparative In Vitro Study Using EGFR-Positive Breast Cancer Cells, International Journal of Biological Macromolecules, 103 (2017) 275-285.
  • [14] Cadena D.L., Gill G.N., Receptor Tyrosine Kinases, FASEB J., 6 (1992) 2332-2337.
  • [15] Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P., Prognostic Value of The Type I Growth Factor Receptors in A Large Series of Human Primary Breast Cancers Quantified with A Real-Time Reverse Transcription polymerase Chain Reaction Assay, Clin. Cancer Res., 6 (2000) 4217-4225.
  • [16] Gullick W.J., Prevalence of Aberrant Expression of The Epidermal Growth Factor, Br. Med. Bull., 47 (1991) 87-98.
  • [17] Mao R.D., Tan Y.M., Expressions of EGFR and p16 Protein in Nasopharyngeal Cancer, Pract. J. Cancer, 14 (1999) 182-184.
  • [18] Gan H.K., Walker F., Burgess A.W., Rigopoulos A., Scott A.M., Johns T.G., The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers, Journal of Biological Chemistry, 282(5) (2007) 2840-2850.
  • [19] Al-Obeidi F.A., Lam K.S., Development of Inhibitors for Protein Tyrosine Kinases, Oncogene, 19(49) (2000) 5690-5701.
  • [20] Johns T.G., Luwor R.B., Murone C., Walker F., Weinstock J., Vitali A.A. et al., Antitumor Efficacy of Cytotoxic Drugs and The Monoclonal Antibody 806 Is Enhanced by The EGF Receptor Inhibitor AG1478, Proceedings of the National Academy of Sciences, 100(26) (2003) 15871-15876.
  • [21] Topçul M.R., Çetin İ., Endpoint of Cancer Treatment: Targeted Therapies, Asian Pacific Journal of Cancer Prevention, 15(11) (2014) 4395-4403.
  • [22] Kawai M., Nakashima A., Kamada S., Kikkawa U., Midostaurin Preferentially Attenuates Proliferation of Triple-Negative Breast Cancer Cell Lines Through Inhibition of Aurora Kinase Family, Journal of Biomedical Science, 22 (1) (2015) 48.
  • [23] Bishop P.C., Myers T., Robey R., Fry D.W., Liu E.T., Blagosklonny M.V., et al., Differential Sensitivity of Cancer Cells to Inhibitors of The Epidermal Growth Factor Receptor Family, Oncogene, 21 (2002) 119-127.
  • [24] Zhang Y.G., Du Q., Fang W.G., Jin M.L., Tian X.X., Tyrphostin AG1478 Suppresses Proliferation and Invasion of Human Breast Cancer Cells, International Journal of Oncology, 33(3) (2008) 595.
  • [25] Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D. et al., EGFR Tyrosine Kinase Inhibitor AG1478 Inhibits Cell Proliferation and Arrests Cell Cycle in Nasopharyngeal Carcinoma Cells, Cancer Letters, 169(1) (2001) 27-32.
  • [26] Nagane N., Levitzki A., Gazit A., Cavanee W.K., Huang H.J., Drug Resistance of Human Glioblastoma Cells Conferred by A Tumour Specific Mutant Epidermal Growth Factor Receptor Through Modulation of Bcl-XL and Caspase 3-Like Proteases, Proc. Natl. Acad. Sci. USA, 95(10) (1998) 5724-5729.
  • [27] Shushan A., Rojansky N., Laufer N., Klein B.Y., Shlomai Z., Levitzki R. et al., The AG1478 Tyrosine Kinase Inhibitor Is An Effective Suppressor Of Leiomyoma Cell Growth, Hum. Reprod., 19 (2004) 1957-1967.
  • [28] Partik G., Hochegger K., Schörkhuber M., Marian B., Inhibition of Epidermal-Growth-Factor-Receptor-Dependent Signalling by Tyrphostins A25 and AG1478 Blocks Growth and Induces Apoptosis in Colorectal Tumour Cells In Vitro, J. Cancer Res. Clin. Oncol., 125 (1999) 379-388.
  • [29] Lei W., Mayotte E.J., Levitt L.M., Enhancement of Chemosensitivity and Programmed Cell Death by Tyrosine Kinase Inhibitors Correlates with EGFR Expression in Non-Small Cell Lung Cancer Cells, Anticancer Res., 19 (1999) 221-228.
  • [30] He H.Y., Fang W.G., Zheng J., You J.F., Heng W.J., Li Y., Mechanisms of Mitogen Activated Protein Kinase Phosphatase-5 Regulation Growth and Invasion of A Human Prostate Cancer Cell Line, Natl. Med. J. China, 83 (2003) 1812-1817.
  • [31] Nakamura H., Takamori S., Fujii T., Ono M., Yamana H., Kuwano M. et al., Cooperative cell growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer, Cancer Lett., 230 (2005) 33-46.
  • [32] Yi H., Wu M., Zhang Q., Lu L., Yao H., Chen S et al., Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells, J. Cancer, 11(13) (2020) 3713-3716.
  • [33] Tian M., Schiemann W.P., GF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells, J. Cancer Metastasis Treat., 3 (2017) 150-160.
  • [34] Cirillo F., Pellegrino M., Malivindi R., Rago V., Avino S., Muto L., GPER is involved in the regulation of the estrogen-metabolizing CYP1B1 enzyme in breast cancer, Oncotarget, 8(63) (2017)106608-106624.
  • [35] Lim E., Metzger-Filho O., Winer E.P., The Natural History of Hormone Receptor-Positive Breast Cancer, Oncology, 26 (2012) 688-694.
  • [36] Tsonis A.I., Afratis N., Gialeli C., Ellina M.I., Piperigkou Z., Skandalis S.S. et al., Evaluation of The Coordinated Actions of Estrogen Receptors with Epidermal Growth Factor Receptor and Insulin‐Like Growth Factor Receptor in The Expression of Cell Surface Heparan Sulfate Proteoglycans and Cell Motility in Breast Cancer Cells, FEBS Journal, 280(10) (2013) 2248-2259

Effects of EGFR inhibitor AG 1478 on MDA-MB-231 and MCF-7 breast cancer cells

Year 2021, Volume: 42 Issue: 4, 758 - 765, 29.12.2021

Nazlı İşlen , Mehmet Rıfkı Topçul

https://izlik.org/JA93HL44GS

Abstract

In this current study, antiproliferative effect of EGFR inhibitor AG1478 was investigated in human breast cancer cell lines. MDA-MB-231 and MCF-7 cell lines were used respectively as triple negative breast cancer and Luminal A breast cancer model. To this end cell viability, cell index values by xCELLigence Real‐Time Cell Analysis DP instrument and mitotic index analysis were used. The results of the current study showed that AG1478 had cytostatic effects on both of cell lines. The IC50 concentration was determined as 50 µM for MDA-MB-231 and 20 µM for MCF-7 cell line. IC50 concentration was used for mitotic index parameter. IC50 concentrations decreased the mitotic index values of both of cell lines. There were significant differences between the control and the experimental groups (p<0.05). The results of the present study suggest that AG1478 may serve as a promising treatment option for breast cancer.

Keywords

In vitro Breast cancer MDA-MB-231 MCF-7 EGFR inhibitor.

Project Number

FYL-2016-21025

References

  • [1] Russo J., Russo I.H., Development of The Human Breast, Maturitas, 49(1) (2004) 2-15.
  • [2] Bahreyni A., Samani S.S., Rahmani F., Behnam‐Rassouli R., Khazaei M., Ryzhikov M. et al., Role of Adenosine Signaling in The Pathogenesis of Breast Cancer, Journal of Cellular Physiology, 233(3) (2018) 1836-1843.
  • [3] Topçul M., Çetin İ., Breast Cancer, Cancer: Disease of the Age, In: (Ed.) Ahmed M El-Sharkawy, Chapter 19, OMICS Group eBooks, Foster City, USA, (2015) 1-21.
  • [4] Board P.C.G.E., Genetics of Breast and Gynecologic Cancers (PDQ®), (2016).
  • [5] Schulz W.A., Breast Cancer, In: Schulz WA (Ed.). Molecular Biology of Human Cancers, Springer, Germany, (2005) 357-382.
  • [6] Weber G.F., Epithelial Tumors, In: Weber GF (Ed.). Molecular Mechanisms of Cancer, Springer, USA, (2007) 441-524.
  • [7] Tryggvadottir L., Olafsdottir E.J., Gudlaugsdottir S., Thorlacius S., Jonasson J.G., Tulinius H. et al., BRCA2 Mutation Carriers, Reproductive Factors and Breast Cancer Risk, Breast Cancer Research, 5(5) (2003) R121.
  • [8] Narod S.A., Modifiers of Risk of Hereditary Breast and Ovarian Cancer, Nat. Rev. Cancer, 2 (2002) 113-123.
  • [9] Vidarsson H., Mikaelsdottir E.K., Rafnar T., Bertwistle D., Ashworth A., Eyfjord J.E. et al., BRCA1 and BRCA2 Bind Stat5a and Suppress Its Transcriptional Activity, FEBS Letters, 532(1-2) (2002) 247-252.
  • [10] Yarden Y., Ullrich A., Growth Factor Receptor Tyrosine Kinases, Annu Rev Biochem., 57 (1988) 443-478.
  • [11] Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R. et al., Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer, Gene, 366(1) (2006) 2-16.
  • [12] Demirelli F.H., Hedefe yönelik kanser tedavisi ve monoklonal antikorlar, Antibiyotik ve Kemoterapi Derneği (ANKEM) Dergisi, 19 (2005) 123-125.
  • [13] Mehrabi M., Mansouri K., Soleymani B., Hoseinkhani Z., Shahlaie M., Khodarahmi R., Development of A Human Epidermal Growth Factor Derivative with EGFR-Blocking and Depleted Biological Activities: A Comparative In Vitro Study Using EGFR-Positive Breast Cancer Cells, International Journal of Biological Macromolecules, 103 (2017) 275-285.
  • [14] Cadena D.L., Gill G.N., Receptor Tyrosine Kinases, FASEB J., 6 (1992) 2332-2337.
  • [15] Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P., Prognostic Value of The Type I Growth Factor Receptors in A Large Series of Human Primary Breast Cancers Quantified with A Real-Time Reverse Transcription polymerase Chain Reaction Assay, Clin. Cancer Res., 6 (2000) 4217-4225.
  • [16] Gullick W.J., Prevalence of Aberrant Expression of The Epidermal Growth Factor, Br. Med. Bull., 47 (1991) 87-98.
  • [17] Mao R.D., Tan Y.M., Expressions of EGFR and p16 Protein in Nasopharyngeal Cancer, Pract. J. Cancer, 14 (1999) 182-184.
  • [18] Gan H.K., Walker F., Burgess A.W., Rigopoulos A., Scott A.M., Johns T.G., The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers, Journal of Biological Chemistry, 282(5) (2007) 2840-2850.
  • [19] Al-Obeidi F.A., Lam K.S., Development of Inhibitors for Protein Tyrosine Kinases, Oncogene, 19(49) (2000) 5690-5701.
  • [20] Johns T.G., Luwor R.B., Murone C., Walker F., Weinstock J., Vitali A.A. et al., Antitumor Efficacy of Cytotoxic Drugs and The Monoclonal Antibody 806 Is Enhanced by The EGF Receptor Inhibitor AG1478, Proceedings of the National Academy of Sciences, 100(26) (2003) 15871-15876.
  • [21] Topçul M.R., Çetin İ., Endpoint of Cancer Treatment: Targeted Therapies, Asian Pacific Journal of Cancer Prevention, 15(11) (2014) 4395-4403.
  • [22] Kawai M., Nakashima A., Kamada S., Kikkawa U., Midostaurin Preferentially Attenuates Proliferation of Triple-Negative Breast Cancer Cell Lines Through Inhibition of Aurora Kinase Family, Journal of Biomedical Science, 22 (1) (2015) 48.
  • [23] Bishop P.C., Myers T., Robey R., Fry D.W., Liu E.T., Blagosklonny M.V., et al., Differential Sensitivity of Cancer Cells to Inhibitors of The Epidermal Growth Factor Receptor Family, Oncogene, 21 (2002) 119-127.
  • [24] Zhang Y.G., Du Q., Fang W.G., Jin M.L., Tian X.X., Tyrphostin AG1478 Suppresses Proliferation and Invasion of Human Breast Cancer Cells, International Journal of Oncology, 33(3) (2008) 595.
  • [25] Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D. et al., EGFR Tyrosine Kinase Inhibitor AG1478 Inhibits Cell Proliferation and Arrests Cell Cycle in Nasopharyngeal Carcinoma Cells, Cancer Letters, 169(1) (2001) 27-32.
  • [26] Nagane N., Levitzki A., Gazit A., Cavanee W.K., Huang H.J., Drug Resistance of Human Glioblastoma Cells Conferred by A Tumour Specific Mutant Epidermal Growth Factor Receptor Through Modulation of Bcl-XL and Caspase 3-Like Proteases, Proc. Natl. Acad. Sci. USA, 95(10) (1998) 5724-5729.
  • [27] Shushan A., Rojansky N., Laufer N., Klein B.Y., Shlomai Z., Levitzki R. et al., The AG1478 Tyrosine Kinase Inhibitor Is An Effective Suppressor Of Leiomyoma Cell Growth, Hum. Reprod., 19 (2004) 1957-1967.
  • [28] Partik G., Hochegger K., Schörkhuber M., Marian B., Inhibition of Epidermal-Growth-Factor-Receptor-Dependent Signalling by Tyrphostins A25 and AG1478 Blocks Growth and Induces Apoptosis in Colorectal Tumour Cells In Vitro, J. Cancer Res. Clin. Oncol., 125 (1999) 379-388.
  • [29] Lei W., Mayotte E.J., Levitt L.M., Enhancement of Chemosensitivity and Programmed Cell Death by Tyrosine Kinase Inhibitors Correlates with EGFR Expression in Non-Small Cell Lung Cancer Cells, Anticancer Res., 19 (1999) 221-228.
  • [30] He H.Y., Fang W.G., Zheng J., You J.F., Heng W.J., Li Y., Mechanisms of Mitogen Activated Protein Kinase Phosphatase-5 Regulation Growth and Invasion of A Human Prostate Cancer Cell Line, Natl. Med. J. China, 83 (2003) 1812-1817.
  • [31] Nakamura H., Takamori S., Fujii T., Ono M., Yamana H., Kuwano M. et al., Cooperative cell growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer, Cancer Lett., 230 (2005) 33-46.
  • [32] Yi H., Wu M., Zhang Q., Lu L., Yao H., Chen S et al., Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells, J. Cancer, 11(13) (2020) 3713-3716.
  • [33] Tian M., Schiemann W.P., GF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells, J. Cancer Metastasis Treat., 3 (2017) 150-160.
  • [34] Cirillo F., Pellegrino M., Malivindi R., Rago V., Avino S., Muto L., GPER is involved in the regulation of the estrogen-metabolizing CYP1B1 enzyme in breast cancer, Oncotarget, 8(63) (2017)106608-106624.
  • [35] Lim E., Metzger-Filho O., Winer E.P., The Natural History of Hormone Receptor-Positive Breast Cancer, Oncology, 26 (2012) 688-694.
  • [36] Tsonis A.I., Afratis N., Gialeli C., Ellina M.I., Piperigkou Z., Skandalis S.S. et al., Evaluation of The Coordinated Actions of Estrogen Receptors with Epidermal Growth Factor Receptor and Insulin‐Like Growth Factor Receptor in The Expression of Cell Surface Heparan Sulfate Proteoglycans and Cell Motility in Breast Cancer Cells, FEBS Journal, 280(10) (2013) 2248-2259
There are 36 citations in total.

Details

Primary Language English
Subjects Structural Biology
Journal Section Research Article
Authors

Nazlı İşlen 0000-0003-3429-2251

Mehmet Rıfkı Topçul 0000-0002-9685-9404

Project Number FYL-2016-21025
Submission Date May 5, 2021
Acceptance Date October 21, 2021
Publication Date December 29, 2021
IZ https://izlik.org/JA93HL44GS
Published in Issue Year 2021 Volume: 42 Issue: 4

Cite

APA İşlen, N., & Topçul, M. R. (2021). Effects of EGFR inhibitor AG 1478 on MDA-MB-231 and MCF-7 breast cancer cells. Cumhuriyet Science Journal, 42(4), 758-765. https://izlik.org/JA93HL44GS

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December